361 related articles for article (PubMed ID: 32477121)
21. MDMX under stress: the MDMX-MDM2 complex as stress signals hub.
de Polo A; Vivekanandan V; Little JB; Yuan ZM
Transl Cancer Res; 2016 Dec; 5(6):725-732. PubMed ID: 30319942
[TBL] [Abstract][Full Text] [Related]
22. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
23. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription.
White DE; Talbott KE; Arva NC; Bargonetti J
Cancer Res; 2006 Apr; 66(7):3463-70. PubMed ID: 16585169
[TBL] [Abstract][Full Text] [Related]
24. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination.
Lee MH; Lee SW; Lee EJ; Choi SJ; Chung SS; Lee JI; Cho JM; Seol JH; Baek SH; Kim KI; Chiba T; Tanaka K; Bang OS; Chung CH
Nat Cell Biol; 2006 Dec; 8(12):1424-31. PubMed ID: 17086174
[TBL] [Abstract][Full Text] [Related]
25. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
26. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
[TBL] [Abstract][Full Text] [Related]
27. p53: An Attractive Therapeutic Target for Cancer.
Patel KR; Patel HD
Curr Med Chem; 2020; 27(22):3706-3734. PubMed ID: 31223076
[TBL] [Abstract][Full Text] [Related]
28. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
[TBL] [Abstract][Full Text] [Related]
29. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
[TBL] [Abstract][Full Text] [Related]
30. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Carr MI; Roderick JE; Zhang H; Woda BA; Kelliher MA; Jones SN
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15024-15029. PubMed ID: 27956626
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
33. MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
Azer SA
J Clin Med; 2018 Mar; 7(4):. PubMed ID: 29584707
[TBL] [Abstract][Full Text] [Related]
34. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
35. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene.
Wu L; Levine AJ
Mol Med; 1997 Jul; 3(7):441-51. PubMed ID: 9260156
[TBL] [Abstract][Full Text] [Related]
36. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
37. Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis.
Lai CW; Xie C; Raufman JP; Xie G
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008383
[TBL] [Abstract][Full Text] [Related]
38. Recent advances of p53-MDM2 small molecule inhibitors (2011-present).
Lv PC; Sun J; Zhu HL
Curr Med Chem; 2015; 22(5):618-26. PubMed ID: 25439588
[TBL] [Abstract][Full Text] [Related]
39. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
[TBL] [Abstract][Full Text] [Related]
40. The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.
Simerzin A; Zorde-Khvalevsky E; Rivkin M; Adar R; Zucman-Rossi J; Couchy G; Roskams T; Govaere O; Oren M; Giladi H; Galun E
Hepatology; 2016 Nov; 64(5):1623-1636. PubMed ID: 27302319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
